Induction of multiple anti-c-erbB-2 specificities accompanies a classical idiotypic cascade following 2B1 bispecific monoclonal antibody treatment

@article{Clark1997InductionOM,
  title={Induction of multiple anti-c-erbB-2 specificities accompanies a classical idiotypic cascade following 2B1 bispecific monoclonal antibody treatment},
  author={Joseph I Clark and R Katherine Alpaugh and Margaret von Mehren and Josephine Schultz and Julie R. Gralow and Martin A. Cheever and David B. Ring and Louis M. Weiner},
  journal={Cancer Immunology, Immunotherapy},
  year={1997},
  volume={44},
  pages={265-272}
}
 The bispecific monoclonal antibody (bsmAb) 2B1, targeting the extracellular domain of c-erbB-2, the protein product of the HER-2/neu proto-oncogene, and FcγRIII (CD16), expressed by human natural killer cells, neutrophils and differentiated monocytes, mediates the specific cytotoxic activity of these effector cells to tumor cells. A group of 24 patients with c-erbB-2-overexpressing tumors were treated with intravenously administered 2B1 in a phase I clinical trial and followed after treatment… CONTINUE READING

5 Figures & Tables

Connections & Topics

Mentioned Connections BETA
The bispecific monoclonal antibody ( bsmAb ) 2B1 , targeting the extracellular domain of c - erbB-2 , the protein product of the HER-2/neu proto - oncogene , and FcγRIII ( CD16 ) , expressed by human natural killer cells , neutrophils and differentiated monocytes , mediates the specific cytotoxic activity of these effector cells to tumor cells .
Induction of multiple anti - c - erbB-2 specificities accompanies a classical idiotypic cascade following 2B1 bispecific monoclonal antibody treatment .
The bispecific monoclonal antibody ( bsmAb ) 2B1 , targeting the extracellular domain of c - erbB-2 , the protein product of the HER-2/neu proto - oncogene , and FcγRIII ( CD16 ) , expressed by human natural killer cells , neutrophils and differentiated monocytes , mediates the specific cytotoxic activity of these effector cells to tumor cells .
Manipulations of 2B1 therapy effects that augment immunity to c - erbB-2 could provide additional avenues for immunotherapy with this and other bispecific antibodies .
The bispecific monoclonal antibody ( bsmAb ) 2B1 , targeting the extracellular domain of c - erbB-2 , the protein product of the HER-2/neu proto - oncogene , and FcγRIII ( CD16 ) , expressed by human natural killer cells , neutrophils and differentiated monocytes , mediates the specific cytotoxic activity of these effector cells to tumor cells .
The bispecific monoclonal antibody ( bsmAb ) 2B1 , targeting the extracellular domain of c - erbB-2 , the protein product of the HER-2/neu proto - oncogene , and FcγRIII ( CD16 ) , expressed by human natural killer cells , neutrophils and differentiated monocytes , mediates the specific cytotoxic activity of these effector cells to tumor cells .
Induction of multiple anti - c - erbB-2 specificities accompanies a classical idiotypic cascade following 2B1 bispecific monoclonal antibody treatment .
Manipulations of 2B1 therapy effects that augment immunity to c - erbB-2 could provide additional avenues for immunotherapy with this and other bispecific antibodies .
All Topics